Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Breathe, breathe in the air: the anti-CCN2 antibody pamrevlumab (FG-3019) completes a successful phase II clinical trial for idiopathic pulmonary fibrosis

Published:2019-12 Issue:4 Volume:13 Page:441-442
ISSN:1873-9601
Container-title:Journal of Cell Communication and Signaling
language:en
Short-container-title:J. Cell Commun. Signal.

Author:

Leask Andrew

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,Biochemistry

Link

http://link.springer.com/content/pdf/10.1007/s12079-019-00542-6.pdf

Reference21 articles.

1. Allen JT, Knight RA, Bloor CA, Spiteri MA (1999) mEnhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 21:693–700

2. Brenner MC, Krzyzanski W, Chou JZ, Signore PE, Fung CK, Guzman D, Li D, Zhang W, Olsen DR, Nguyen VT, Koo CW, Sternlicht MD, Lipson KE (2016) FG-3019, a human monoclonal antibody recognizing connective tissue growth factor, is subject to target-mediated drug disposition. Pharm Res 33:1833–1849

3. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, Takehara K (1995) Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 105:280–284

4. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106:729–733

5. Kinashi H, Falke LL, Nguyen TQ, Bovenschen N, Aten J, Leask A, Ito Y, Goldschmeding R (2017) Connective tissue growth factor regulates fibrosis-associated renal lymphangiogenesis. Kidney Int 92:850–863

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blocking CCN2 Reduces Established Palmar Neuromuscular Fibrosis and Improves Function Following Repetitive Overuse Injury;International Journal of Molecular Sciences;2023-09-08

2. Let’s Focus on the Fibrosis in Dupuytren Disease: Cell Communication Network Factor 2 as a Novel Target;Journal of Hand Surgery Global Online;2023-09

3. Blocking CCN2 Reduces Established Bone Loss Induced by Prolonged Intense Loading by Increasing Osteoblast Activity in Rats;JBMR Plus;2023-06-16

4. Remodeling of the Lamina Cribrosa: Mechanisms and Potential Therapeutic Approaches for Glaucoma;International Journal of Molecular Sciences;2022-07-22

5. Idiopathic pulmonary fibrosis: Current and future treatment;The Clinical Respiratory Journal;2022-01-10